MK 966
Categoria
MK 966 Nombres de marca, MK 966 Analogos
MK 966 Marca los nombres de mezcla
MK 966 Formula quimica
C17H14O4S
MK 966 RX enlace
http://www.rxlist.com/cgi/generic/rofecox.htm
MK 966 FDA hoja
MK 966 MSDS (hoja de seguridad de materiales)
MK 966 Sintesis de referencia
No hay información disponible
MK 966 Peso molecular
314.357 g/mol
MK 966 Punto de fusion
No information avaliable
MK 966 H2O Solubilidad
Insoluble
MK 966 Estado
Solid
MK 966 LogP
3.019
MK 966 Formas de dosificacion
Tablet (12,5 mg, 25 mg o 50 mg), la suspensión oral (12,5 o 25 mg por ml de solución 5)
MK 966 Indicacion
Para el tratamiento de la osteoartritis, dolor agudo en adultos y el dolor menstrual.
MK 966 Farmacologia
Rofecoxib, un ciclooxigenasa-2 (COX-2) inhibidores, se clasifica como antiinflamatorios no esteroideos (AINE). Rofecoxib es utilizado por sus actividades anti-inflamatorias, analgésicas y antipiréticas en el manejo de la osteoartritis (OA) y para el tratamiento de la dismenorrea o dolor agudo. A diferencia de celecoxib, rofecoxib carece de una cadena sulfonamida y no requiere de enzimas del citocromo P450 para el metabolismo.
MK 966 Absorcion
La biodisponibilidad oral media de rofecoxib a dosis terapéuticamente recomendada de 12,5, 25 y 50 mg es aproximadamente del 93%.
MK 966 Toxicidad
No hay sobredosis de rofecoxib fueron reportados durante los ensayos clínicos. La administración de dosis únicas de rofecoxib de 1000 mg a 6 voluntarios sanos y en dosis múltiples de 250 mg / día durante 14 días a 75 voluntarios sanos no produjo toxicidad grave.
MK 966 Informacion de Pacientes
PATIENT INFORMATION
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
MK 966 Organismos afectados
Humanos y otros mamíferos
